Abstract:Background: The robustness and reproducibility of transcriptomics-derived models were limited by the various microenvironmental conditions like stromal context and tumor purity. We aimed to explore a robust prognostic and immunotherapeutic predictive model by differentiating cell origins in lung adenocarcinoma (LUAD).Methods: A total of 2,451 patients in 12 independent cohorts with transcriptomic data, including 10 public datasets and two in-house cohorts, were analyzed. The tumor immune cell score (TICS) and tumor stromal score (TSCS) was developed depending on the candidate immune or stromal cells in the training meta-cohorts (n=6), and then verified in four datasets. Therapeutic responses including immune checkpoint inhibitors (ICIs), chemotherapy and tyrosine kinase inhibitor (TKI) were compared between high- and low- TICS groups in the advanced-stage LUAD.Finding: The TICS, instead of TSCS, contributed majorly for predicting clinical outcomes in LUAD. The high TICS was associated with a prolonged overall survival (OS) in the training meta-cohorts (HR 0·55, 95%CI 0·45-0·66) and was validated in three public cohorts and one in-house cohort. The prognostic efficacy of TICS was more significant in the early-stage LUAD (HR=0·49, 95%CI: 0·38-0·63). For the advanced-stage LUAD, high TICS predicted a superior OS in patients who treated with ICIs (HR 0·09, 95% CI 0·02-0·32) instead of chemotherapy (HR 0·84, 95% CI 0·30-2·30) or TKI (HR 1·20, 95% CI 0·08-20·00).Interpretation: TICS is associated with survival in patients with LUAD, and may serve as a predictor for the benefit of ICIs in advanced LUAD.Funding Information: National Natural Sciences Foundation (82102886 for JX); Beijing Nova Program (Z211100002121055 for ZY); the Special Research Fund for Central Universities, Peking Union Medical College (3332021029 for JX); National Natural Sciences Foundation (82203827 for ZY); the Special Research Fund for Central Universities, Peking Union Medical College (3332021028 for ZY); Beijing Natural Science Foundation (7222146 for ZY); Guangdong Association of Clinical Trials (GACT) /Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120); Beijing Hope Run Special Fund of Cancer Foundation of China (LC2021B22, LC2020B09, LC2020A33); the National Natural Sciences Foundation (81871889 and 82072586 for ZW) and Beijing Natural Science Foundation (7212084 for ZW).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: All patients have informed consent and this study was approved by the ethics committees of the National Cancer Center (NCC-22/250-3454, NCC-22/429-3631). Patients without follow-up information were removed from further evaluation.

Additional File 1 of Integration of Single-Cell Regulon Atlas and Multi-Omics Data for Prognostic Stratification and Personalized Treatment Prediction in Human Lung Adenocarcinoma

Integration of single-cell regulon atlas and multi-omics data for prognostic stratification and personalized treatment prediction in human lung adenocarcinoma

Additional File 2: of A Large Cohort Study Identifying a Novel Prognosis Prediction Model for Lung Adenocarcinoma Through Machine Learning Strategies

Additional File 6: of A Large Cohort Study Identifying a Novel Prognosis Prediction Model for Lung Adenocarcinoma Through Machine Learning Strategies

Identification of Genes Associated with Lung Adenocarcinoma Prognosis

Additional File 3: Table S5. of Differential Expression Analysis at the Individual Level Reveals a Lncrna Prognostic Signature for Lung Adenocarcinoma

A&nbsp;Novel Prognostic and Immunotherapeutic Predictive Model Based On&nbsp;cell-Originated Characterization of Tumor Microenvironment in Lung Adenocarcinoma

Additional File 2 of IRGS: an Immune-Related Gene Classifier for Lung Adenocarcinoma Prognosis

Histopathological Images and Multi-Omics Integration Predict Molecular Characteristics and Survival in Lung Adenocarcinoma

Supplementary Figures S1-S21 from Integrated Multi-Omics Analysis of Early Lung Adenocarcinoma Links Tumor Biological Features with Predicted Indolence or Aggressiveness

Integrative Proteomic Characterization of Human Lung Adenocarcinoma

Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals

Integrated single-cell RNA sequencing analysis reveals distinct cellular and transcriptional modules associated with survival in lung cancer

Additional File 1 of Prognostic Risk Assessment Model and Drug Sensitivity Analysis of Colon Adenocarcinoma (COAD) Based on Immune-Related Lncrna Pairs

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma

A Single-Cell Characterised Signature Integrating Heterogeneity and Microenvironment of Lung Adenocarcinoma for Prognostic Stratification

Uncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer

Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma

Subclassification of lung adenocarcinoma through comprehensive multi-omics data to benefit survival outcomes

Additional File 3 of Exploration of Predictive and Prognostic Alternative Splicing Signatures in Lung Adenocarcinoma Using Machine Learning Methods

Multi-omics characterization and machine learning of lung adenocarcinoma molecular subtypes to guide precise chemotherapy and immunotherapy